Works matching DE "APREMILAST"
Results: 182
Apremilast retention rate in clinical practice: observations from an Italian multi-center study.
- Published in:
- Clinical Rheumatology, 2022, v. 41, n. 10, p. 3219, doi. 10.1007/s10067-022-06255-3
- By:
- Publication type:
- Article
Apremilast and narrowband ultraviolet B combination therapy suppresses Th17 axis and promotes melanogenesis in vitiligo skin: a randomized, split-body, pilot study in skin types IV–VI.
- Published in:
- Archives of Dermatological Research, 2023, v. 315, n. 2, p. 215, doi. 10.1007/s00403-022-02343-1
- By:
- Publication type:
- Article
Apremilast induced intolerable dizziness: A rare unlisted adverse effect.
- Published in:
- Indian Journal of Drugs in Dermatology, 2023, v. 9, n. 2, p. 80, doi. 10.4103/ijdd.ijdd_12_23
- By:
- Publication type:
- Article
Evaluating the efficacy of apremilast combined with low-dose steroids versus combination of apremilast with low-dose steroids and low-dose aspirin for selected cases in the management of erythema nodusum leprosum: A pilot study.
- Published in:
- Indian Journal of Drugs in Dermatology, 2023, v. 9, n. 1, p. 13, doi. 10.4103/ijdd.ijdd_47_21
- By:
- Publication type:
- Article
Gratifying results of apremilast in unstable erythrodermic psoriasis.
- Published in:
- Indian Journal of Drugs in Dermatology, 2022, v. 8, n. 1, p. 40, doi. 10.4103/ijdd.ijdd_27_21
- Publication type:
- Article
Improving the solubility and permeability of apremilast with cyclodextrin encapsulation for the development of local drug delivery systems.
- Published in:
- Macedonian Pharmaceutical Bulletin / Makedonsko Farmacevtski Bilten, 2023, v. 69, p. 209, doi. 10.33320/maced.pharm.bull.2023.69.03.103
- By:
- Publication type:
- Article
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 8, p. 2235, doi. 10.1007/s13555-024-01224-x
- By:
- Publication type:
- Article
Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 7, p. 1891, doi. 10.1007/s13555-024-01201-4
- By:
- Publication type:
- Article
Exploratory Efficacy Evaluation of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: 32-Week Results from a Phase 2, Randomized, Placebo-Controlled Study.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 7, p. 1863, doi. 10.1007/s13555-024-01195-z
- By:
- Publication type:
- Article
Consistent Efficacy of Apremilast in Patients with Psoriasis Regardless of Baseline Disease Severity or Special Area Involvement: Subgroup Analysis from PROMINENT.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 6, p. 1587, doi. 10.1007/s13555-024-01179-z
- By:
- Publication type:
- Article
Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 3, p. 627, doi. 10.1007/s13555-024-01109-z
- By:
- Publication type:
- Article
Correction: Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Correction to: The Needs of Patients with Psoriasis and Benefits of Apremilast in French Clinical Practice: Results from the Observational REALIZE Study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Early Discontinuation of Apremilast in Patients with Psoriasis and Gastrointestinal Comorbidities: Rates and Associated Risk Factors.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 9, p. 2019, doi. 10.1007/s13555-023-00975-3
- By:
- Publication type:
- Article
Apremilast Adherence and Persistence in Patients with Psoriasis and Psoriatic Arthritis in the Telehealth Setting Versus the In-person Setting During the COVID-19 Pandemic.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 9, p. 1973, doi. 10.1007/s13555-023-00967-3
- By:
- Publication type:
- Article
The Needs of Patients with Psoriasis and Benefits of Apremilast in French Clinical Practice: Results from the Observational REALIZE Study.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 6, p. 1361, doi. 10.1007/s13555-023-00933-z
- By:
- Publication type:
- Article
Apremilast in Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Meta-analysis.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 2, p. 437, doi. 10.1007/s13555-022-00877-w
- By:
- Publication type:
- Article
Efficacy and Safety of Apremilast in the Treatment of Patients with Mild-to-Moderate Psoriasis in Japan: Results from PROMINENT, A Phase 3b, Open-Label, Single-Arm Study.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 6, p. 1469, doi. 10.1007/s13555-022-00747-5
- By:
- Publication type:
- Article
Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 451, doi. 10.1007/s13555-021-00659-w
- By:
- Publication type:
- Article
Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 203, doi. 10.1007/s13555-021-00658-x
- By:
- Publication type:
- Article
Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 1, p. 81, doi. 10.1007/s13555-021-00628-3
- By:
- Publication type:
- Article
Successful treatment with apremilast for palmar, yet not plantar, plaque psoriasis in a pediatric patient.
- Published in:
- Our Dermatology Online / Nasza Dermatologia Online, 2023, v. 14, n. 2, p. 219, doi. 10.7241/ourd.20232.25
- By:
- Publication type:
- Article
Thermosensitive In Situ Gel of Nanosized Apremilast: Development and Assessment for Rheumatoid Arthritis Treatment.
- Published in:
- Nano Life, 2024, v. 14, n. 2, p. 1, doi. 10.1142/S1793984424500028
- By:
- Publication type:
- Article
Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience.
- Published in:
- 2023
- By:
- Publication type:
- Letter to the Editor
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Key Advances in Oral Therapies for Psoriasis Unveiled at Winter Clinical Dermatology Conference 2025.
- Published in:
- 2025
- By:
- Publication type:
- Abstract
Plaque-Psoriasis: Langzeitdaten bestätigen positives Sicherheitsprofil von Deucravacitinib.
- Published in:
- Kompass Dermatologie, 2024, v. 12, n. 4, p. 219, doi. 10.1159/000542195
- By:
- Publication type:
- Article
Therapeutic Effects of Apremilast on Enthesitis and Dactylitis in Real Clinical Setting: An Italian Multicenter Study.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 12, p. 3892, doi. 10.3390/jcm12123892
- By:
- Publication type:
- Article
Predictors of DAPSA Response in Psoriatic Arthritis Patients Treated with Apremilast in a Retrospective Observational Multi-Centric Study.
- Published in:
- Biomedicines, 2023, v. 11, n. 2, p. 433, doi. 10.3390/biomedicines11020433
- By:
- Publication type:
- Article
Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis.
- Published in:
- Biomedicines, 2022, v. 10, n. 6, p. 1303, doi. 10.3390/biomedicines10061303
- By:
- Publication type:
- Article
Apremilast Ameliorates Experimental Arthritis <italic>via</italic> Suppression of Th1 and Th17 Cells and Enhancement of CD4<sup>+</sup>Foxp3<sup>+</sup> Regulatory T Cells Differentiation.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.01662
- By:
- Publication type:
- Article
An Open-Label, Randomized, Prospective, Comparative, Three-Arm Clinical Trial to Evaluate the Safety and Effectiveness of Apremilast with Three Different Titration Methods in Patients with Chronic Plaque Psoriasis in India.
- Published in:
- Psoriasis: Targets & Therapy, 2022, v. 12, p. 53, doi. 10.2147/PTT.S357184
- By:
- Publication type:
- Article
Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score.
- Published in:
- Clinical & Experimental Dermatology, 2024, v. 49, n. 10, p. 1148, doi. 10.1093/ced/llae131
- By:
- Publication type:
- Article
Apremilast for the treatment of papuloerythroderma of Ofuji.
- Published in:
- Clinical & Experimental Dermatology, 2023, v. 48, n. 11, p. 1282, doi. 10.1093/ced/llad265
- By:
- Publication type:
- Article
Evolving utility of apremilast in dermatological disorders for off‐label indications.
- Published in:
- Clinical & Experimental Dermatology, 2022, v. 47, n. 12, p. 2136, doi. 10.1111/ced.15377
- By:
- Publication type:
- Article
Effect of Oral Drug Apremilast on Histopathological Changes in Patients of Plaque Psoriasis: A Prospective Observational Study.
- Published in:
- Journal of Clinical & Diagnostic Research, 2023, v. 17, n. 3, p. 1, doi. 10.7860/JCDR/2023/60263.17537
- By:
- Publication type:
- Article
Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2023, v. 16, p. 1899, doi. 10.2147/CCID.S417679
- By:
- Publication type:
- Article
Evaluation of the Efficacy and Safety of Apremilast in the Management of Lichen Planus.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2022, v. 15, p. 2593, doi. 10.2147/CCID.S390591
- By:
- Publication type:
- Article
Apremilast in the Treatment of Plaque Psoriasis: Differential Use in Psoriasis.
- Published in:
- Clinical, Cosmetic & Investigational Dermatology, 2022, v. 15, p. 395, doi. 10.2147/CCID.S266036
- By:
- Publication type:
- Article
Inside Cover Picture.
- Published in:
- Chinese Journal of Chemistry, 2024, v. 42, n. 19, p. 2274, doi. 10.1002/cjoc.202490192
- Publication type:
- Article
Divergent Protein Engineering of Transaminase for the Synthesis of Chiral Rivastigmine and Apremilast Precursors<sup>†</sup>.
- Published in:
- Chinese Journal of Chemistry, 2024, v. 42, n. 19, p. 2335, doi. 10.1002/cjoc.202400351
- By:
- Publication type:
- Article
What insights can be gained from optimizing the relevant research on methotrexate monotherapy versus methotrexate and apremilast combination therapy in the treatment of palmoplantar psoriasis?
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2024, v. 90, n. 2, p. 1, doi. 10.25259/IJDVL_337_2023
- By:
- Publication type:
- Article
Darier disease responding to apremilast: Report of two cases.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2024, v. 90, n. 2, p. 1, doi. 10.25259/IJDVL_83_2023
- By:
- Publication type:
- Article
Long-Term Effectiveness and Drug Survival of Apremilast in Treating Psoriasis: A Real-World Experience.
- Published in:
- Dermatology (10188665), 2022, v. 238, n. 2, p. 267, doi. 10.1159/000515763
- By:
- Publication type:
- Article
PDE4 Gene Family Variants Are Associated with Response to Apremilast Treatment in Psoriasis.
- Published in:
- Genes, 2024, v. 15, n. 3, p. 369, doi. 10.3390/genes15030369
- By:
- Publication type:
- Article
Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort.
- Published in:
- Acta Dermato-Venereologica, 2022, v. 102, p. 1, doi. 10.2340/actadv.v101.566
- By:
- Publication type:
- Article
Effectiveness of Apremilast in Real Life in Patients with Psoriasis: A Longitudinal Study.
- Published in:
- Acta Dermato-Venereologica, 2021, v. 101, n. 9, p. 1, doi. 10.2340/00015555-3846
- By:
- Publication type:
- Article
Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
- Published in:
- Acta Dermato-Venereologica, 2016, v. 96, n. 4, p. 514, doi. 10.2340/00015555-2360
- By:
- Publication type:
- Article
Long‐term effectiveness and tolerability of apremilast in patients with moderate‐to‐severe plaque psoriasis: A 5‐year multicentre retrospective study—IL PSO (Italian landscape psoriasis).
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 11, p. e946, doi. 10.1111/jdv.20003
- By:
- Publication type:
- Article
Effective management of severe chronic erythema nodosum leprosum in adolescent patient using ustekinumab and apremilast: A case report.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 3, p. e244, doi. 10.1111/jdv.19552
- By:
- Publication type:
- Article